Borresen-Dale AL - Search Results

1

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.

Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. Petitjean A, et al. Oncogene. 2007 Apr 2;26(15):2157-65. doi: 10.1038/sj.onc.1210302. Oncogene. 2007. PMID: 17401424 Review.

2

TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival.

Børresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E. Børresen-Dale AL, et al. Clin Cancer Res. 1998 Jan;4(1):203-10. Clin Cancer Res. 1998. PMID: 9516972

3

Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines.

Sørlie T, Martel-Planche G, Hainaut P, Lewalter J, Holm R, Børresen-Dale AL, Montesano R. Sørlie T, et al. Br J Cancer. 1998 May;77(10):1573-9. doi: 10.1038/bjc.1998.259. Br J Cancer. 1998. PMID: 9635831 Free PMC article.

4

TP53 and breast cancer.

Børresen-Dale AL. Børresen-Dale AL. Hum Mutat. 2003 Mar;21(3):292-300. doi: 10.1002/humu.10174. Hum Mutat. 2003. PMID: 12619115 Review.

5

Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.

Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A. Wang Y, et al. Hum Mutat. 2004 Jul;24(1):21-34. doi: 10.1002/humu.20055. Hum Mutat. 2004. PMID: 15221786

6

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.

Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Børresen-Dale AL. Olivier M, et al. Clin Cancer Res. 2006 Feb 15;12(4):1157-67. doi: 10.1158/1078-0432.CCR-05-1029. Clin Cancer Res. 2006. PMID: 16489069

7

TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.

Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS. Langerød A, et al. Breast Cancer Res. 2007;9(3):R30. doi: 10.1186/bcr1675. Breast Cancer Res. 2007. PMID: 17504517 Free PMC article.

8

TP53 Mutations in Breast and Ovarian Cancer.

Silwal-Pandit L, Langerød A, Børresen-Dale AL. Silwal-Pandit L, et al. Cold Spring Harb Perspect Med. 2017 Jan 3;7(1):a026252. doi: 10.1101/cshperspect.a026252. Cold Spring Harb Perspect Med. 2017. PMID: 27815305 Free PMC article. Review.

9

Genetic variants of CYP19 (aromatase) and breast cancer risk.

Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Kåresen R, Kristensen T, Børresen-Dale AL. Kristensen VN, et al. Oncogene. 2000 Mar 2;19(10):1329-33. doi: 10.1038/sj.onc.1203425. Oncogene. 2000. PMID: 10713674

10

The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas.

Langerød A, Bukholm IR, Bregård A, Lønning PE, Andersen TI, Rognum TO, Meling GI, Lothe RA, Børresen-Dale AL. Langerød A, et al. Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1684-8. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12496062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

507 results

Search Page